NCT01058473 Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain Status COMPLETED Phase N/A
NCT01049854 CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Status COMPLETED Phase PHASE2
NCT01048905 Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension Status COMPLETED Phase PHASE2
NCT01033227 Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease Status TERMINATED Phase PHASE1/PHASE2
NCT01000155 Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease Status TERMINATED Phase PHASE2
NCT00999245 THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA) Status TERMINATED Phase PHASE3
NCT00972231 Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia Status COMPLETED Phase N/A
NCT00968162 Sickle Cell Disease Conditioning for Bone Marrow Transplant Status COMPLETED Phase PHASE1
NCT00957931 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Status COMPLETED Phase PHASE2
NCT00951808 Preventing Acute Chest Syndrome by Transfusion Feasibility Study Status COMPLETED Phase NA
NCT00940901 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia Status COMPLETED Phase PHASE2
NCT00911495 Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease Status COMPLETED Phase PHASE1/PHASE2
NCT00895154 A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study Status COMPLETED Phase NA
NCT00880373 Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine Status TERMINATED Phase PHASE4
NCT00850369 A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension Status WITHDRAWN Phase PHASE2
NCT00842088 Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease Status COMPLETED Phase PHASE1/PHASE2
NCT00834899 A Safety Study of Eptifibatide in Patients With Sickle Cell Disease Status TERMINATED Phase PHASE1/PHASE2